Skip to main content

Advertisement

Table 9 Blood Lipid and Glucose Panel

From: Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance

Variable Treatment Time (h) p-level
0 2
Cholesterol PLA 170.6 ± 34.6 182.8 ± 35.1 0.006
(mg/dl) PWS 187.3 ± 46.6 a 180.2 ± 36.9
PWS + S 161.7 ± 29.8 a,b 174.0 ± 33.5 a
HDL-c PLA 54.9 ± 13.3 60.1 ± 16.0 0.57
(mg/dl) PWS 52.2 ± 13.9 58.9 ± 14.6
PWS + S 54.2 ± 16.2 60.1 ± 18.1
CHOL: HDL-c PLA 3.2 ± 0.9 b 3.2 ± 0.9 0.001
PWS 3.8 ± 1.3 a,c 3.2 ± 1.0 *
PWS + S 3.2 ± 1.0 b 3.1 ± 1.0
LDL-c PLA 104.3 ± 36.7 109.6 ± 41.2 0.55
(mg/dl) PWS 96.9 ± 31.9 104.5 ± 36.0
PWS + S 99.8 ± 41.2 104.6 ± 40.7
Triglycerides PLA 98.0 ± 58.6 89.3 ± 38.3 0.14
(mg/dl) PWS 109.5 ± 56.8 100.3 ± 47.5
PWS + S 88.3 ± 42.2 92.8 ± 54.6
Glucose PLA 90.2 ± 9.7 101.5 ± 14.4 * 0.03
(mg/dl) PWS 100.1 ± 16.0 a,c 114.4 ± 12.6 *a
PWS + S 90.4 ± 7.3 113.8 ± 15.0 *a
  1. Values are means ± standard deviations for total cholesterol (CHOL), high density lipoproteins (HDL-c), the CHOL: HDL ratio (CHOL: HDL-c), low density lipoproteins (LDL-c), triglycerides and blood glucose. MANOVA analysis revealed overall Wilks’ Lambda treatment (p < 0.001), time (p < 0.001), and treatment x time (p < 0.001). Greenhouse-Geisser univariate p-levels of interaction (treatment x time) are reported above. * represents p < 0.05 difference from baseline. a denotes a significant difference from PLA. b denotes a significant difference from PWS. c denotes a significant difference from PWS + S